Institutional members access full text with Ovid®

Share this article on:

Brief Report: Prolonged Viral Suppression Over a 12-Year Follow-up of HIV-Infected Patients The Persistent Impact of Adherence at 4 Months After Initiation of Combined Antiretroviral Therapy in the ANRS CO8 APROCO-COPILOTE Cohort

Protopopescu, Camelia PhD; Carrieri, Maria P. PhD; Raffi, François MD, PhD; Picard, Odile MD; Hardel, Lucile MSc; Piroth, Lionel MD, PhD; Jadand, Corinne MD; Pierret, Janine PhD; Spire, Bruno MD, PhD; Leport, Catherine MD, PhDthe ANRS CO8 APROCO-COPILOTE Study Group

JAIDS Journal of Acquired Immune Deficiency Syndromes: March 1st, 2017 - Volume 74 - Issue 3 - p 293–297
doi: 10.1097/QAI.0000000000001249
Implementation Science

Abstract: The effect of early adherence on long-term viral suppression was assessed among 1281 patients with HIV starting a protease inhibitor-containing regimen in 1997–1999, followed up to 12 years. Association between 4-month adherence (3-level score) and prolonged viral suppression was evaluated using a multivariate mixed logistic model in 891 eligible patients. High 4-months adherence [odds ratio (95% confidence interval): 3.72 (1.98 to 6.98)] was associated with long-term prolonged viral suppression, irrespective of maintenance adherence. This unexpected long-term virological impact of early adherence reinforces the message that, when starting antiretrovirals, all means should be mobilized to ensure optimum early adherence to achieve prolonged antiretroviral success.

Supplemental Digital Content is Available in the Text.

*INSERM, UMR_S 912 (SESSTIM), Marseille, France;

Aix Marseille Université, UMR_S 912, IRD, Marseille, France;

ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France;

§CMIT, Paris, France;

Hôpital St Antoine, Paris, France;

INSERM, ISPED, Centre INSERM U1219 Bordeaux Population Health, Bordeaux, France;

#CHU Dijon, Dijon, France;

**Université Paris Diderot, INSERM, IAME, UMR 1137, Paris, France;

††CERMES (CNRS-INSERM-EHESS), Paris, France; and

‡‡Unité de Coordination du Risque Épidémique et Biologique, Assistance Publique-Hôpitaux de Paris, Paris, France.

Correspondence to: Camelia Protopopescu, PhD, Faculté de Médecine, INSERM, UMR_S 912 (SESSTIM), 27 Boulevard Jean Moulin, 13385 Marseille Cedex 5, France (e-mail:

The ANRS CO8 (APROCO-COPILOTE) cohort is funded by ANRS (Agence Nationale de Recherches sur le Sida et les hépatites virales) and CMIT (Collège des Universitaires de Maladies Infectieuses et Tropicales), which received research grants from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Pfizer, and Roche. The funders did not interfere with data analysis or interpretation and dissemination of the scientific results.

The authors have no conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (

Received June 01, 2016

Accepted October 19, 2016

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.